US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges
Risdiplam Launch Among 2020 Tests
Executive Summary
Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.
You may also be interested in...
Zolgensma Stands Out In Strong Q4 For Novartis
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.